Myriad Genetics, Inc. (MYGN)

Market Cap	432.57M +15.3%
Revenue (ttm)	829.00M -0.3%
Net Income	-399.90M
EPS	-4.29
Shares Out	94.45M
PE Ratio	n/a
Forward PE	40.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,571
Open	4.590
Previous Close	4.570
Day's Range	4.590 - 4.640
52-Week Range	3.530 - 8.590
Beta	1.73
Analysts	Hold
Price Target	6.25 (+36.46%)
Earnings Date	May 5, 2026

About MYGN

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 5, 1995
• Employees: 2,700
• Stock Exchange: NASDAQ
• Ticker Symbol: MYGN
• Website: https://www.myriad.com

Financial Performance

In 2025, Myriad Genetics's revenue was $824.50 million, a decrease of -1.56% compared to the previous year's $837.60 million. Losses were -$365.90 million, 187.4% more than in 2024.

Analyst Summary

According to 9 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price target is $6.25, which is an increase of 36.46% from the latest price.

Price Target

$6.25

(36.46% upside)

Analyst Consensus: Hold